@Goutam_Chak

Assistant Professor, PhD, Cancer researcher, Cell Biologist @IcahnMountSinai. Passionate about Science and Photography, Views are my own

 New York
labs.icahn.mssm.edu/chakrabortylab/
Joined July 2019
  • Tweets855
  • Following745
  • Followers615
93Media
Thrilled to share our latest publication on castration resistance published in @CellReports cell.com/cell-reports/fullte… Key Discoveries BCL2 a driver of early castration resistance. Crosstalk in AR-BCL2-PI3K signaling pathways. Venetoclax + ENZ combo delated CSPC growth.

BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating recipr...

Hirani et al. show how androgen-deprivation therapy (ADT)-induced crosstalk between oncogenic cell signaling pathways, driven by BCL2, contributes to castration-resistant prostate cancer (CRPC). This...

cell.com
8
5
1
33
1,683
Congratulations to Postdoctoral Fellow Prathiksha Prabhakaraalva to present her research at NYC NCI postdoc Scientific Symposium #chakrabortylab @TischCancer @MountsinaiUro @IcahnMountSinai #prostatecancer
11
314
Thank you @soulehoward1 for your support to early career investigators like us and for your leadership @PCF_Science @PCFnews
2
2
20
860
A full hall standing ovation to Dr Mary-Ellen Taplin at #PCFRretrat26 @PCFnews @PCF_Science
2
10
473
Goutam Chakraborty retweeted
Samson W. Fine, MD@rovingatuscapSep 30
Prostate cancer displaying cells w/histologically visible neuroendocrine granules (so-called 'Paneth cell-like', though lack lysozyme & +NE markers unlike GI cells) - important to differentiate from small cell/high-grade NE carcinoma - can be seen in any grade of PCa
1
15
1
46
3,043
Thrilled to be appointed as the #AssociatedDirector , Shared Resources, at NCI designated Tisch Cancer Center at Icahn School of Medicine at Mount Sinai. A new chapter in my #academicjourney. @TischCancer @IcahnMountSinai @MountsinaiUro #research #cancercellbiologists
3
2
25
1,374
Goutam Chakraborty retweeted
The Harvard Crimson
@thecrimsonSep 21
NIH Director Jay Bhattacharya, a former colleague of Harvard President Alan Garber, refused a directive from Trump on Friday to cut Harvard’s federal research grants, Politico reported Saturday. @HugoChiassonn and @EliseSpenner report. thecrimson.com/article/2026/…

NIH Director Bhattacharya Refuses Trump Demand to Cut Harvard Funding, Politico Reports

NIH Director Bhattacharya Refuses Trump Demand to Cut Harvard Funding, Politico Reports

thecrimson.com
18
188
19
542
117,708
Goutam Chakraborty retweeted
Leslie Vosshall PhD
@leslievosshallSep 18
Transformative opportunity for early career faculty @hhmi_science #FreemanHrabowski Scholars competition opens 11/3/2026 but you can get started NOW: view application components, establish eligibility, and unlock example applications and other resources hhmi.org/programs/freeman-hr…

Early Career Faculty Program | Freeman Hrabowski Scholars | HHMI

The Freeman Hrabowski Scholars Program offers comprehensive support to outstanding early career faculty committed to scientific excellence in their own research, and to fostering labs that expand the...

hhmi.org
1
22
2
72
22,918
Goutam Chakraborty retweeted
Anirban Maitra@Aiims1742Aug 16
The Maitra Lab @nyulangone @Perlmutter_CC is recruiting for a research scientist, with immediate availability. Please see the announcement below. We are excited to grow our #PancreaticCancer research team as we approach the one year mark in NYC!
1
23
1
87
10,968
Goutam Chakraborty retweeted
Bravo-Cordero Lab@BravoCorderoLabAug 3
🚨We're growing! Our lab at @TischCancer is #recruiting postdocs for 3 fully funded NIH projects. If you want to explore the biology of tumor dormancy, join us!!! Projects focus on:🧠Cancer neuroscience, ECM-driven dormancy, HER2 biology. 📩 email for more info or send your CV👇
3
42
1
137
11,976
Happy 250th Birthday "The United States of America".
2
49
Goutam Chakraborty retweeted
Raunak Shrestha, PhD@raunakmsJul 2
🧬 We're Hiring: Postdoctoral Fellow – Computational Biology & Machine Learning The Shrestha Lab at the @CPDR_Labs, Bethesda, MD is looking for motivated Postdocs to join our team 📌 More Details: iaaxmg.fa.ocs.oraclegovcloud… #Hiring #Postdoc #ComputationalBiology #MachineLearning

Postdoctoral Fellow - Computational Biology & Machine Learning

HJF is seeking Postdoctoral Fellow - Computational Biology & Machine Learning who will be responsible for initiating and carrying out research projects in collaboration with a research team consist...

iaaxmg.fa.ocs.oraclegovcloud.com
1
6
611
Goutam Chakraborty retweeted
Marcus Ruscetti Lab@Marcus_RuscettiJun 25
We are recruiting a postdoc to work on an NIH funded project to determine the role of aging and oncogene-induced stromal senescence on prostate cancer initiation and therapy resistance. See job posting and recent publication below. ummsjobs.com/job/11591/ aacrjournals.org/cancerdisco…
13
16
1,071
Goutam Chakraborty retweeted
Sounak Sahu@SounakSahuJan 13
✨ New Year, New Lab, New Beginnings ✨ Join us in New York as we are building our team. We are interested in understanding the molecular and cellular mechanisms underlying human breast development, tissue homeostasis, and breast cancer. sahulab.com Please RT.
3
15
2
54
7,496
Goutam Chakraborty retweeted
NEJM
@NEJMMay 31
Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO
Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.

52
2,043
444
5,575
2,630,386
Goutam Chakraborty retweeted
Jame Abraham, MD, FACP
@jamecancerdocMay 31
Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO #ASCO26 @OncoAlert
11
174
13
1,191
105,754
Laboratory Visit of Dr. Richard Izquierdo Health & Science Charter School AP bio high sc student at #chakrabortlab @IcahnMountSinai @MountsinaiUro @TischCancer #stem . Discussing our reaseach with high school student to inspire them for their career goal. – at Manhattan, NY
2
56
Goutam Chakraborty retweeted
Mukund Iyengar
@mukundiyngrMay 19
Cancer survival in the U.S. just crossed 70%. It was 63% in the 1990s. That gap = 4.8M people alive today. This one chart captures survival gains across 29 cancer types. The wins are real. So is the unfinished work. ▪️CML: 31% → 72% ▪️Multiple myeloma: 32% → 62% ▫️Kidney: 59% → 82% ▫️Metastatic melanoma: 16% → 35% ▫️Childhood ALL: 80% → 92% But some cancers barely moved. Cervical cancer outcomes actually worsened. None of this is abstract progress, though. These are birthdays, grandkids, and years of life returned. This is what funded science does. Next time someone asks if cancer research works, show them this (full) chart. - - - - - Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health - - - - -
16
139
8
379
32,426
NIH is proudly prioritizing drug repurposing as a way to accelerate research while using resources efficiently. Watch for some outstanding examples of how we’ve applied gold standard science to find new ways existing therapies can benefit more patients now:
56
81
14
454
33,537
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications onlinelibrary.wiley.com/doi/… BRCA1/2🧬 reversion mutations, which restore BRCA function and confer PARP inhibitor resistance, were identified in advanced #ProstateCancer both after and without prior PARP inhibitor exposure. In this retrospective liquid biopsy study, 30% of PARP-naïve patients with BRCA reversions had received chemotherapy and radiation, suggesting DNA-damaging therapies may promote reversion and primary resistance, supporting earlier PARP inhibitor use. @DougLinMD @MaxMaomaoYe @OGjoerup @RyonGraf @RichardHuangMD @DouglasMab3lt @DrRanaMcKay @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists
21
37
2,509
Load more